Insulin Marketing Negotiations Biocon in Negotiations with Bristol-Myers and Aventis-Sanofi for Global Insulin Marketing

Editor: Dominik Stephan

Indian biopharmaceutical company Biocon is said to be negotiating with international partners about the marketing rights for its oral insulin IN105.

Related Companies

(Picture: Biocon)
(Picture: Biocon)

Mumbai/India – The Indian Economic Times recently reported of talks between Biocon and Bristol-Myers Squibb as well as Aventis-Sanofi about the selling of marketing rights for Biocon's oral insulin IN105. The total transaction amount could be valued about US $ 1 billion could include combination of upfront payments, milestone-linked payments and royalties on sales of the drug, the Economic Times reported. Bristol-Myers Squibb and Biocon have already partnered on a contract manufacturing for Bristol-Myers by Biocon's subsidary Syngene.

Biocon is currently expanding it's business market with the help of strategic partnerships. The Indian company already signed a strategic US $ 350 million deal with Pfizer in October 2010 for the commercialisation for Biocon's biosimilar insulins and insulin analog products - Recombinant Human Insulin, Glargine, Aspart and Lispro. Insulin Anlogs are altered forms of insulin, that differ from natural insulin but can still be used by the human body for the glycemic control just like human insulin.